Global Naloxone Market to Grow at an Estimated CAGR of 10.5% During the forecast Period 2021-2030

The Naloxone market is projected to grow at a CAGR of 10.5% during the forecast period from 2021 to 2030. Naloxone is an opioid antagonist designed to rapidly reverse opioid overdose. Naloxone can restore the normal respiration of a person whose breathing has stopped or slowed down due to opioid or heroin overdose. Currently, opioid abuse is one of the foremost causes of drug overdose and is a leading cause of death globally. However, it is more common in North America and Europe.

The opioid crisis in the U.S. has reached epidemic proportions, leading to serious healthcare costs and losses of resources. The urgent need for better treatment and growth in numbers of people suffering from opioid dependence is resulting in the growth in the U.S. naloxone market. Opioid dependence is a serious concern globally, with more than 25 million people affected. The problem exists in both developed as well as developing countries but is greatest in the United States.

The increasing prevalence of opioid overdoses is expected to drive the growth of the naloxone market. An increasing incidence of opioid drug abuse in both the developed and developing worlds remains the key driver for the market growth of the naloxone market. On average, more than 130 people in America die each day from an opioid overdose.

Based on the formulation/route of administration, the naloxone market is categorized as parenteral, intranasal, and sublingual. The parenteral segment contributed highest to the market revenues. Hospitals still remain the key resort when individuals are overdosed, and parenteral remains the key preferred administration method among healthcare professionals. However, during the forecast period, there have been significant changes in the market compared to the base year of 2021.  

Browse the full report at: https://www.atlanticmarketresearch.com/naloxone-market

Based on dosage/strength, the naloxone market is segmented into 0.4mg/ml, 1mg/1ml, 0.4mg/0.4ml and 4 mg/0.1 ml. 0.4mg/ml led the market revenues ($ 1530.9 million) in 2020. However, there is only a minor difference between 4mg/0.1 ml and the other dosages, which stand second in terms of 2020 revenues. The most recommended injections are dosed as 0.4mg at the start of the treatment.

With respect to sales channels, the market is segmented based on hospital pharmacy, outpatient retail pharmacy, online pharmacy, and others. Hospital pharmacies were the prime point of sales for naloxone in 2020, as the primary place of emergency treatment is still hospitals. For individuals who do not require hospitals, outpatient retail pharmacies remain the key point of sales. Online and other channels were not significantly popular in 2020.

The largest market, North America, was worth $ 1665 Mn in 2020 and is expected to grow at a CAGR of 10.4% during the forecast period of 2021 to 2030. Asia Pacific grew at the fastest rate of 11.2% CAGR from 2021 to 2030 due to emerging market potential that is promising a higher uptake of naloxone during the forecast period.Asia Pacific is observed to be the most attractive region for the naloxone market owing to a swift growth in the uptake of medicines to prevent surging death rates.

Indivior remains at the top position with respect to product portfolio and business strength. Key companies in naloxone market include Indivor, Orexo, Emergent Biosolutions, Viatris, Novartis, Amphastar Pharmaceuticals, Hospira, Mundipharma, Kern Pharma, UCB and Others

KEY MARKET MOVEMENTS

• The Naloxone market is projected to grow at a CAGR of 10.5% during the forecast period from 2021 to 2030.
• An increasing incidence of opioid drug abuse in both the developed and developing worlds remains the key driver for the market growth of the naloxone market.
• The parenteral segment contributed highest to the market revenues.
• The most recommended injections are dosed as 0.4mg at the start of the treatment.
• Hospital pharmacies were the prime point of sales for naloxone in 2020, as the primary place of emergency treatment is still hospitals.
• The largest market, North America, was worth $ 1665 Mn in 2020 and is expected to grow at a CAGR of 10.4% during the forecast period of 2021 to 2030.
• Asia Pacific grew at the fastest rate of 11.2% CAGR from 2021 to 2030.
• Indivior remains at the top position with respect to product portfolio and business strength. Key companies in naloxone market include Indivor, Orexo, Emergent Biosolutions, Viatris, Novartis, Amphastar Pharmaceuticals, Hospira, Mundipharma, Kern Pharma, UCB and Others

Tags: